Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06304623Phase 1Completed

SVF for Treating Pulmonary Fibrosis Post COVID-19

Role: collaborator

NCT05154591Phase 1Completed

CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells

Role: collaborator

NCT05699161Phase 1Completed

Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

Role: collaborator

NCT02615886Not ApplicableCompleted

Pilot Feasibility of Rice Bran Supplementation in Nicaraguan Children

Role: collaborator

All 4 trials loaded